top of page

Video Guide

video512x512.png

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:
Search
Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

AZTR

Phase 1b

ATR-12

Netherton syndrome

Early 2025

4/18/24- Preclinical data on May 10th at ASGCT '24 & 17th, & 23rd of May 2024 at various conferences. 8/21/24- First patient screened and schedules to enroll. Interim safety data in early 2025 with full results by H2 2025. 8/28/24- First patient dosed

Data readout

MGNX

Phase 2

Vobramitamab duocarmazine (vobra duo) (MGC018)

mCRPC (metastatic Castration-resistant Prostate Cancer)

early 2025

TAMARACK study. 4/3/24- Early interim safety data. 5/9/24 Updated interim data. 9/15/24- Presented Ph2 data at ESMO '24. Final data w/ rPFS no later than early 2025.

Data readout

ARVN

Phase 1

ARV-102

Parkinson’s disease

April 1-4, 2025

2/20/24 First-in-Human Dosed in Ph1 study. Continue enrollment & begin enrolling in the MAD by end of 2024. 1/10/25- Present SAD data at AD/PD conference on April 1-4, 2025. Complete enrollment and present initial data in 2025.

Data readout

ALDX

PDUFA

Reproxalap (ADX-102)

DED (Dry Eye Disease)

April 2, 2025

2/7/23- NDA accepted and assigned a PDUFA date of November 23, 2023. 10/16/23- FDA concluded that another efficacy trial necessary. 11/27/23- Received CRL. 8/8/24- Reported primary endpoint. 10/3/24- Resubmitted NDA. 11/18/24- NDA acceptance for review. PDUFA date April 2, 2025.

Approval decision

VIGL

Phase 1

VG-3927

Alzheimer’s Disease

April 1-5, 2025

7/24/24- Reported interim data. 9/17/24- FDA lifted partial clinical hold. 1/23/25- Reported data from completed Ph1 trial. 3/13/25- Present add'l data at AD/PD 2025 on April 1-5, 2025. Initiate Ph2 trial in Q3 2025.

Additional data readout

CNTA

Phase 2a

ORX750

Narcolepsy/ sleep-wake disorders (Type and Type 2)

April 5, 2025

CRYSTAL-1 trial. 9/10/24- Ph1 interim data. 3/7/25- Ph1 trial poster presentation at AAN'25 on April 5, 2025. 3/24/25- Share Ph2a data in 2025.

Data readout

AMGN

Phase 3

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb)

Myasthenia Gravis

April 8, 2025

MINT: Initiated a Phase 3 trial in Q4 2020. 10/6/23- Acquisition of HZNP closed asset from HZNP. 10/15/24 Positive Ph3 data & present at AANEM '24. 3/13/25- New data reported and set to be presented at AAN '25 on April 8, 2025.

Data readout

ARGX

PDUFA

VYVGART SC pre-filled syringe (PFS)

generalized myasthenia gravis (gMG), CIDP

April 10, 2025

10/31/24 PDUFA date for PFS set on 4/10/25.

Approval decision

Meeting

Biomedical meeting

ASGCT Annual Meeting

Gene and Cell therapies

Apr 14, 2025

ASGCT '25: Abstracts (Regular and Late) Media Release Date April 14, 2025. Regular abstracts embargoed on April 28, 2025 and late-breaking abstracts on May 9, 2025.

Abstract Release

THTX

PDUFA

EGRIFTA SV® (tesamorelin for injection)

HIV-Associated Excess Abdominal Fat

April 18, 2025

Initial U.S. Approval: 2010. 2/21/25- Review of Prior Approval Supplement (PAS) ongoing with PDUFA goal date of April 18, 2025.

Approval decision

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20

bottom of page